Overview
BASECARE-B (2170)
Suzhou Basecare Medical Corporation Limited, an investment holding company provides genetic testing solutions for assisted human reproduction in the People’s Re...
- Open
- 1.400
- High
- 1.400
- Low
- 1.295
- Prev. Close
- 1.370
- Volume
- 64.00K
- Turnover
- 86.76K
- Avg Price
- 1.356
- Bid/Ask Ratio
- -25.58%
- Amplitude
- 7.66%
- 52wk High
- 2.470
- Volume Ratio
- 2.98
- Turnover Ratio
- 0.08%
- 52wk Low
- 1.200
- HK Mkt Cap
- 109.66M
- Market CapHKD
- 364.39M
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.734
- EPSDynamic
- -0.608
- EPSStatic
- --
- BVPS
- 3.65
- P/B
- 0.37
- HK Shares
- 82.14M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 272.95M
- Min lot size
- 500
- Currency
- HKD
BASECARE-B Analyst Rating
View moreForecast & Rating
Jul 1, 2026- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
BaseCare Medical (2170.HK) spiked and faded, opening at HK$1.400, which was also the session high, before sliding to HK$1.300 at 11:20 BJ and closing at HK$1.335, down 2.55% on just 64,000 shares. Repeated next-day disclosure returns tied to its RMB5 million buy-back and a cumulative repurchase programme still failed to hold the HK$1.40 level. H1 FY2026 revenue rose 27% to RMB128.75 million with the net loss narrowing 40.7% to RMB72.05 million, while Q2 revenue of HK$74.36 million grew 33.9% year on year yet net margin stayed at -55.96%. At HK$1.335 the stock sits on MA60 of HK$1.333 and below MA20 of HK$1.346, down 32.23% year to date and 45.95% below the 52-week high of HK$2.47. Though the absolute loss and ROE of -16.66% indicate the earnings inflection is not yet confirmed.
- Nov, 4
BaseCare Medical probed lower and recovered, closing at HK$1.35, down 0.7% from the prior close of HK$1.36: it opened at the session high of HK$1.36, slid to HK$1.27 by 10:53 BJ, then clawed back to HK$1.35 by the 16:00 close on just 80,500 shares and HK$108,855 of turnover (0.10% turnover rate), suggesting selling pressure eased after the prior session's roughly 7% drop. Support traces to buybacks, including 43,000 shares for HK$58,700 on November 2 and a near-daily repurchase run through late October, alongside State Council language on a birth-friendly society that lifted maternal and infant themes. Fundamentals remain in loss-narrowing mode: Q2 2026 revenue of HK$74.36 million rose 33.9% year on year, net loss narrowed 37.5% to HK$41.61 million and operating loss improved 48.55%, yet net margin stayed at -55.96%, with PB 0.37 and market cap HK$368.7 million. The stock is down 31.47% year to date, 50.4% below its 52-week high of HK$2.72 and 12.5% above the HK$1.20 low, now above MA20 of 1.324 and MA60 of 1.341, though it remains unprofitable and buyback size is small relative to market cap.
- Oct, 23
Basecare Medical (2170.HK) closed down 2.55% at HK$1.335 on 23 October, shaping a low-open, dip-then-rebound session with a late fade, ranging between HK$1.285 and HK$1.365 on just 85,000 shares and a 0.1% turnover rate. Support came mainly from continuous buybacks: 31,500 shares for HK$43,500 on 22 October, plus 25,500 and 19,500 shares on the 21st and 20th, alongside an H-share repurchase plan capped at RMB 5 million; in September the GEMS vitrification and thawing solution set won a Class III device registration certificate. Q2 2026 revenue reached HK$74.36 million, up 33.92% year on year, with net loss narrowing 37.48% to HK$41.61 million, though the net margin stayed at -55.96%. The stock sits 54.9% below its 52-week high of HK$2.96 and down 32.23% year to date, holding above the 1.291 MA20 but below the 1.349 MA60, with a 0.37 price-to-book. Still, the single-day repurchase size is small, so the bid around HK$1.3 remains to be tested.
- Oct, 22
Successive buybacks and a narrower interim loss lifted 2170.HK 1.48% to HK$1.37, after an afternoon slide to HK$1.29 that was recovered into the close. Basecare repurchased 25,500 shares for HK$34,500 on 21 October, extending a run of small buybacks since 9 October alongside a planned H-share repurchase of up to RMB5 million. Q2 2026 revenue reached HK$74.36 million, up 33.92% year on year, while net loss narrowed to HK$41.61 million, a 37.48% reduction, though net margin stayed at -55.96%. Still, the stock is down 30.46% year to date and sits 53.72% below its 52-week high of HK$2.96, trading above the MA20 of 1.294 with price-to-book at 0.38 times and only HK$45,470 of turnover for the session.
- Sep, 24
Suzhou Basecare Medical opened lower and drifted downward during the morning session, falling from an opening of 1.395 HKD to 1.300 HKD, a decline of 6.81%, with 321 thousand shares traded and turnover of 417,905 HKD. The primary driver was the company's first half FY2026 financial results: net loss narrowed by 40.7% year-over-year to RMB 72.05 million, but revenue grew only 27% to RMB 128.75 million, and the quarterly net profit margin remained at -55.96% with EPS of -0.152 HKD. Positive catalysts such as the NMPA Class III approval for the Gems embryo culture medium and a strategic partnership with RHEA LABS were overshadowed by the persistent losses. The stock now trades at 1.30 HKD, 60.49% below its 52-week high of 3.29 HKD, down 34.01% year-to-date, and below both its 20-day MA of 1.357 HKD and 60-day MA of 1.38 HKD.
News
PUBT · Suzhou Basecare Medical Files HKEX Next-Day Disclosure Return Announcing Share Buyback
Market Movers · BaseCare Medical falls 5% in Hong Kong trading
PUBT · Suzhou Basecare Files Next Day Disclosure Return to HKEX Announcing Share Buyback
PUBT · Anhui Conch Cement Reports Share Buyback in HKEX Next-Day Disclosure Return
PUBT · Suzhou Basecare Medical Files Next-Day Return With HKEX Disclosing Share Repurchase
